ATE429242T1 - METHOD FOR IDENTIFYING COMPOUNDS REGULATING MUSCLE MASS OR FUNCTION USING CORTICOTROPIN RELEASING FACTOR RECEPTORS - Google Patents

METHOD FOR IDENTIFYING COMPOUNDS REGULATING MUSCLE MASS OR FUNCTION USING CORTICOTROPIN RELEASING FACTOR RECEPTORS

Info

Publication number
ATE429242T1
ATE429242T1 AT02731122T AT02731122T ATE429242T1 AT E429242 T1 ATE429242 T1 AT E429242T1 AT 02731122 T AT02731122 T AT 02731122T AT 02731122 T AT02731122 T AT 02731122T AT E429242 T1 ATE429242 T1 AT E429242T1
Authority
AT
Austria
Prior art keywords
function
muscle mass
factor receptors
releasing factor
identifying compounds
Prior art date
Application number
AT02731122T
Other languages
German (de)
Inventor
Robert Isfort
Russell Sheldon
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Application granted granted Critical
Publication of ATE429242T1 publication Critical patent/ATE429242T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
AT02731122T 2001-03-06 2002-03-06 METHOD FOR IDENTIFYING COMPOUNDS REGULATING MUSCLE MASS OR FUNCTION USING CORTICOTROPIN RELEASING FACTOR RECEPTORS ATE429242T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/799,978 US6670140B2 (en) 2001-03-06 2001-03-06 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
PCT/US2002/007476 WO2002069908A2 (en) 2001-03-06 2002-03-06 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors

Publications (1)

Publication Number Publication Date
ATE429242T1 true ATE429242T1 (en) 2009-05-15

Family

ID=25177205

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02731122T ATE429242T1 (en) 2001-03-06 2002-03-06 METHOD FOR IDENTIFYING COMPOUNDS REGULATING MUSCLE MASS OR FUNCTION USING CORTICOTROPIN RELEASING FACTOR RECEPTORS

Country Status (28)

Country Link
US (3) US6670140B2 (en)
EP (1) EP1379873B1 (en)
JP (2) JP4331942B2 (en)
KR (2) KR100596991B1 (en)
CN (1) CN100520408C (en)
AR (1) AR032957A1 (en)
AT (1) ATE429242T1 (en)
AU (1) AU2002303121B2 (en)
BR (1) BR0207881A (en)
CA (1) CA2439170C (en)
CZ (1) CZ20032395A3 (en)
DE (1) DE60232063D1 (en)
ES (1) ES2325485T3 (en)
HU (1) HUP0402173A2 (en)
IL (1) IL157330A0 (en)
MA (1) MA26990A1 (en)
MX (1) MXPA03008114A (en)
MY (1) MY134755A (en)
NO (1) NO20033936L (en)
NZ (1) NZ527124A (en)
PE (1) PE20020993A1 (en)
PL (1) PL367187A1 (en)
RU (1) RU2260805C2 (en)
SA (1) SA02230159B1 (en)
SK (1) SK12132003A3 (en)
TW (1) TWI227780B (en)
WO (1) WO2002069908A2 (en)
ZA (1) ZA200305642B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1305334T3 (en) * 2000-08-04 2009-02-02 Res Dev Foundation Urocortin proteins and uses thereof
AU2001289916A1 (en) * 2000-09-22 2002-04-02 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Methods for improving the antagonistic/agonistic properties of peptidic antagonists/agonists of the corticotropin-releasing factor receptor (crfr)
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
US7192923B2 (en) * 2002-01-16 2007-03-20 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
WO2007090087A2 (en) * 2006-01-27 2007-08-09 Research Development Foundation Use of corticotropin releasing factor receptor-2 inhibitors for treating insulin-related diseases
WO2008047241A2 (en) * 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
GB0624282D0 (en) * 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
JP4824815B2 (en) * 2007-05-23 2011-11-30 ファルマコーム合同会社 G protein-coupled receptor with modified ligand affinity and use thereof
WO2010036918A2 (en) * 2008-09-26 2010-04-01 University Of Massachusetts Intracellular dna receptor
AU2011348068B2 (en) * 2010-12-23 2016-05-05 Amazentis Sa Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
AU2012339722B2 (en) * 2011-11-14 2017-09-14 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A
RU2517259C1 (en) * 2013-03-06 2014-05-27 Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации - Институт медико-биологических проблем Российской академии наук (ГНЦ РФ-ИМБП РАН) Method for preventing and reducing destruction of skeletal proteins of atrophied skeletal muscles caused by hypokinesia and/or discharge by gravity
JP2015071549A (en) * 2013-10-02 2015-04-16 株式会社ファンケル Atrogin-1 inhibitor
RU2568903C2 (en) * 2014-04-07 2015-11-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации Method for assessing anabolic action of medicinal preparations
JP2019533021A (en) 2016-10-20 2019-11-14 コーティーン インコーポレイテッド Methods of treating diseases that contribute to maladaptive stress responses
CN111787981A (en) 2018-03-01 2020-10-16 瑞泽恩制药公司 Method of altering body composition

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415558A (en) 1981-06-08 1983-11-15 The Salk Institute For Biological Studies CRF And analogs
AU9054582A (en) 1982-09-29 1984-04-24 Lederis, K.P., Mac Cannell, K.L.:ichikawa, T:river, J.E. Urotensin peptides
US4489163A (en) 1983-04-14 1984-12-18 The Salk Institute For Biological Studies rCRF and analogs
US4594329A (en) 1984-05-14 1986-06-10 The Salk Institute For Biological Studies CRF analogs
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US4801612A (en) * 1986-07-03 1989-01-31 Regents Of The University Of California Method of inhibiting inflammatory response
DE3703340A1 (en) * 1987-02-04 1988-08-18 Dirck Dr Med Oppermann PHARMACEUTICAL PREPARATION FOR TREATING HEART INSUFFICIENCY
US4908352A (en) 1987-09-28 1990-03-13 The Salk Institute For Biological Studies Urotensin peptides
US5109111A (en) 1988-09-23 1992-04-28 The Salk Institute For Biological Studies CRF antagonists
US5278146A (en) 1988-09-30 1994-01-11 The Salk Institute For Biological Studies CRF analogs
CA1340964C (en) * 1988-09-30 2000-04-18 Jean E. F. Rivier Crf analogs
US5235036A (en) 1991-05-31 1993-08-10 The Salk Institute For Biological Studies Crf analogs
US5493006A (en) 1993-06-16 1996-02-20 The Salk Institute For Biological Studies Cyclic CRF analogs
US5728545A (en) 1993-06-18 1998-03-17 The Salk Institute Of Biological Studies Cloning and recombinant production of CRF receptor (S)
US6495343B1 (en) * 1993-06-18 2002-12-17 The Salk Institute For Biological Studies Cloning and recombinant production of CRF receptor(s)
US5786203A (en) * 1994-06-14 1998-07-28 Neurocrine Biosciences, Inc. Isolated nucleic acid encoding corticotropin-releasing factor2 receptors
JPH10501420A (en) * 1994-06-14 1998-02-10 ニューロクライン バイオサイエンシズ，インコーポレイティド Adrenocorticotropic hormone-releasing factor (2) Receptor
EP0860501A3 (en) 1994-06-14 1999-05-19 Neurocrine Biosciences, Inc. Corticotropin-releasing factor2 receptors
US5663292A (en) 1994-12-12 1997-09-02 The Salk Institute For Biological Studies Cyclic CRF analogs
US5824771A (en) 1994-12-12 1998-10-20 The Salk Institute For Biological Studies Cyclic CRF agonists
US5660824A (en) 1995-05-24 1997-08-26 Grabstein; Kenneth H. Muscle trophic factor
CA2223792A1 (en) 1995-06-13 1997-01-03 The Salk Institute For Biological Studies Urocortin peptides
US5869450A (en) 1996-03-06 1999-02-09 The Regents Of The University Of California Anti-inflammatory compositions and method with corticotropin-releasing factor analogs
US5888811A (en) 1996-05-23 1999-03-30 Dupont Pharmaceuticals Company Corticotropin-releasing hormone receptor
DE69935227T2 (en) * 1998-07-24 2007-10-31 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. FOR THE CORTICOTROPIN RELEASING FACTOR TYPE 2 RECEPTOR (CRFR2) SPECIFIC ANTAGONISTS
DK1305334T3 (en) * 2000-08-04 2009-02-02 Res Dev Foundation Urocortin proteins and uses thereof
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors

Also Published As

Publication number Publication date
HUP0402173A2 (en) 2005-01-28
CZ20032395A3 (en) 2004-01-14
SK12132003A3 (en) 2004-05-04
MXPA03008114A (en) 2003-12-12
WO2002069908A3 (en) 2003-03-20
RU2260805C2 (en) 2005-09-20
NZ527124A (en) 2005-11-25
MA26990A1 (en) 2004-12-20
US20040101911A1 (en) 2004-05-27
IL157330A0 (en) 2004-02-19
JP4331942B2 (en) 2009-09-16
KR100596991B1 (en) 2006-07-07
PE20020993A1 (en) 2002-12-20
US20060198842A1 (en) 2006-09-07
CA2439170A1 (en) 2002-09-12
RU2003129500A (en) 2005-03-10
AR032957A1 (en) 2003-12-03
PL367187A1 (en) 2005-02-21
CN100520408C (en) 2009-07-29
AU2002303121B2 (en) 2005-11-10
DE60232063D1 (en) 2009-06-04
EP1379873A4 (en) 2006-03-22
US6670140B2 (en) 2003-12-30
US7572768B2 (en) 2009-08-11
CA2439170C (en) 2011-05-10
SA02230159B1 (en) 2007-05-06
ZA200305642B (en) 2004-06-22
EP1379873A2 (en) 2004-01-14
TWI227780B (en) 2005-02-11
NO20033936L (en) 2003-11-05
NO20033936D0 (en) 2003-09-05
KR20030086289A (en) 2003-11-07
MY134755A (en) 2007-12-31
US7063954B2 (en) 2006-06-20
WO2002069908A2 (en) 2002-09-12
CN1820200A (en) 2006-08-16
ES2325485T3 (en) 2009-09-07
EP1379873B1 (en) 2009-04-22
KR20060029704A (en) 2006-04-06
KR100598441B1 (en) 2006-07-10
US20030165807A1 (en) 2003-09-04
JP2004532394A (en) 2004-10-21
JP2009029816A (en) 2009-02-12
BR0207881A (en) 2005-08-30

Similar Documents

Publication Publication Date Title
ATE429242T1 (en) METHOD FOR IDENTIFYING COMPOUNDS REGULATING MUSCLE MASS OR FUNCTION USING CORTICOTROPIN RELEASING FACTOR RECEPTORS
DE602005003176D1 (en) Method and apparatus for data transmission using the composition of packets
DE60115653D1 (en) Method for detecting emotions using subgroup specialists
DE60314659D1 (en) System and method for discovering and setting from a server
ATE266749T1 (en) METHOD FOR PREVENTING CORROSION OF METALS USING SILANES
DE602004010306D1 (en) METHOD AND DEVICE FOR IMPROVING DIRECTIONAL ACCURACY AND CONTROL USING BASIC HOLE ASSEMBLY BENDING MEASUREMENTS
DE602004029029D1 (en) COMPOSITIONS AND METHOD FOR IMPROVING THE HEATING RATE OF PET USING ACTIVATED CARBON
DE602005024339D1 (en) Apparatus and method for coordinating multiple scheduling sessions using time constraints
ATE406946T1 (en) METHOD FOR SOLIDIFICATION USING AN ANTI-SOLVENT
DE602004022900D1 (en) A method and apparatus for optical target tracking using a triangulation technique
DE50115863D1 (en) METHOD FOR REGULATING DRIVING STABILITY
DE602004018714D1 (en) Method for providing two-part, self-adhesive dental materials
DE69809592D1 (en) METHOD FOR EPOXYING USING CO2-TREATED SILVER-CONTAINING CATALYSTS
DE60232956D1 (en) METHOD FOR TREATING STRESS-RELATED DISEASES USING GLUCOCORTICOID-RECEPTOR-SPECIFIC ANTAGONISTS
ATE231339T1 (en) METHOD FOR CONTROLLING MOTH MOTH LARVAE
ATE448209T1 (en) METHOD FOR PRODUCING PYRIMIDINE COMPOUNDS
DE69920967D1 (en) METHOD FOR CVD USING BI-ALCOXIDES
DE60307617D1 (en) METHOD FOR OBTAINING GOLD
DE50301044D1 (en) METHOD FOR SELECTION OF TRANSPONDER
DE60203514D1 (en) METHOD FOR ALLOCATING SURFACES
DE60326551D1 (en) METHOD FOR ISOMERIZING HYDROCARBONS
ATE284890T1 (en) METHOD FOR OBTAINING N-PHOSPHONOMETHYLGLYCINE
ATE206392T1 (en) METHOD FOR ALKYLING HINDERED SULFONAMIDS
DE502005003258D1 (en) Method for setting the parameters of electronic engine control for hoists
DE60317607D1 (en) Method of using nonvolatile microbicidal agents

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties